首页 | 本学科首页   官方微博 | 高级检索  
检索        

三氧化二砷与顺铂联用对人乳腺癌细胞杀伤作用的研究
引用本文:张卓,李海新.三氧化二砷与顺铂联用对人乳腺癌细胞杀伤作用的研究[J].河北医药,2009,31(10):1162-1163.
作者姓名:张卓  李海新
作者单位:峰峰集团总医院放疗科,河北省邯郸市,056200;河北省邯郸市中心医院检验科
摘    要:目的探讨三氧化二砷与顺铂联合应用对人乳腺癌细胞的杀伤作用。方法将三氧化二砷与顺铂单独及联合应用于体外培养的乳腺癌MCF-7细胞,采用MTT法测定细胞抑制率,于透射电镜下观察细胞超微结构变化;用流式细胞仪观察细胞凋亡情况。结果1μg/ml三氧化二砷与1μg/ml顺铂联合应用于乳腺癌MCF-7细胞48h后,细胞抑制率为27.01%,明显高于单用三氧化二砷(1μg/ml)时的12.12%及单用顺铂(1μg/ml)时的10.93%。细胞超微结构及流式细胞仪观察均显示,联合应用比单用促凋亡效应更显著(P〈0.01)。结论三氧化二砷与顺铂联合应用,可高效杀伤人乳腺癌细胞,此协同作用主要是通过诱导肿瘤细胞凋亡来实现的。

关 键 词:三氧化二砷  顺铂  凋亡

The lethal effect of As_2O_3 combined with cisplatin on mammary carcinoma cells in vitro
ZHANG Zhuo,LI Haixin.The lethal effect of As_2O_3 combined with cisplatin on mammary carcinoma cells in vitro[J].Hebei Medical Journal,2009,31(10):1162-1163.
Authors:ZHANG Zhuo  LI Haixin
Institution:ZHANG Zhuo,LI Haixin.Department of Radiotherapy,The General Hospital of Fengfeng Group,Hebei,H,an 056200,China
Abstract:Objective To investigate the lethal effect of As2O3 combined with cisplatin on mammary carcinoma cells in vitro. Methods The single As2 O3 or As2 O3 combined with cisplatin were used in cultured MCF-7 mammary carcinoma ceils. The inhibition rate was measured by MTT. Cellular uhrastructure was observed by electron microscope. Cell apoptosis was examined by flow cytometry. Results 48 hours after the combined application of As2O3 1.0 μg/ml and cisplatin 1.0 μg/ml in MCF-7 cells, the inhibition rate was 27. 01%, which was significantly higher than that of the single application of As2O3 1.0 μg/ml ( 12.12% ) or cisplatin 1.0 μg/ml ( 10.93% ). The changes of celluar ultrastructure and flow cytometry suggested that the apoptosis inductive effect of the combined application was much more remarkable than that of the single application ( P 〈0.01 ). Conclusion Combined application of As2O3 and cisplatin can kill effectively MCF-7 cells, which is mainly fulfilled by inducing cell apoptosis.
Keywords:As_2O_3  cisplatin  apoptosis  
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号